Drug intelligence / Profile preview

TKD-010

Development stage: Preclinical
Lead developer: Therakind
Modality: Small Molecules
Administration: Intranasal

Overview

TKD-010 is an intranasal small molecule therapeutic under development by Therakind for the treatment of nausea and vomiting. Therakind specializes in the development of niche medicines and the optimization of existing molecules through novel delivery systems. TKD-010 is designed to provide a rapid-onset, non-invasive treatment option, which is particularly beneficial for patients experiencing active emesis who may have difficulty retaining oral medications. As of 2024, the specific active ingredient and the exact stage of clinical development remain undisclosed by the company.

Beyond the preview

Go deeper on TKD-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TKD-010.

Explore the full profile